Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

Video

In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, discussed the potential future of mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In particular, she mentioned that mirvetuximab soravtansine, which is being assessed in the phase 3 SORAYA trial (NCT04296890) could prove to be a valuable therapy option in a population of patients with limited and less effective treatment options.

Transcript:

This is a really first-in-class antibody-drug conjugate against FRα, and it would be one of the newest drugs since [the] bevacizumab [Avastin] approval [in 2014]. Our patients with platinum-resistant ovarian cancer do not have many options. The use of single-agent chemotherapy [produces] very low response rates of about 10% to 12%, so we need new agents. This definitely represents a new agent with significant anticancer activity, and also a very manageable toxicity profile.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content